Incyte (INCY) Gains from Investment Securities (2016 - 2026)
Incyte (INCY) posted Gains from Investment Securities of -$168000.0 for Q1 2026, up 99.41% on a QoQ basis from -$28.3 million in Q4 2025, and down 101.45% year-over-year from $11.6 million in Q1 2025.
Incyte (INCY) Gains from Investment Securities (2016 - 2026) Analysis & Trends
Incyte's Gains from Investment Securities history runs 11 years deep, the most recent figure standing at -$168000.0 for Q1 2026.
- Quarterly Gains from Investment Securities fell 101.45% year-over-year to -$168000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$17.9 million (down 156.14% YoY) and the FY2025 annual result came in at -$6.1 million, down 130.95% from the prior year.
- Gains from Investment Securities was -$168000.0 for Q1 2026 at Incyte, up from -$28.3 million in the prior quarter.
- Across five years, Gains from Investment Securities topped out at $24.3 million in Q4 2022 and bottomed at -$28.3 million in Q4 2025.
- A 5-year average of $3.2 million and a median of $3.3 million in 2022 frame the typical range for Gains from Investment Securities.
- Annual changes were most pronounced in 2022 — Gains from Investment Securities slumped 852.34% — and 2024, when it soared 5595.31%.
- Incyte's Gains from Investment Securities stood at $24.3 million in 2022, then sank by 38.15% to $15.1 million in 2023, then slumped by 126.86% to -$4.0 million in 2024, then sank by 598.76% to -$28.3 million in 2025, then jumped by 99.41% to -$168000.0 in 2026.
- Business Quant data shows INCY's Gains from Investment Securities at -$168000.0 in Q1 2026, -$28.3 million in Q4 2025, and -$12.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | Incyte | 23.64 Bn | 19.62 Bn | 1.17 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -168,000.00 |
| Mar 31, 2026 | -168,000.00 |
| Dec 31, 2025 | -28.26 Mn |
| Dec 31, 2025 | -28.26 Mn |
| Sep 30, 2025 | -12.20 Mn |
| Sep 30, 2025 | -12.20 Mn |
| Jun 30, 2025 | 22.76 Mn |
| Jun 30, 2025 | 22.76 Mn |
| Mar 31, 2025 | 11.57 Mn |
| Mar 31, 2025 | 11.57 Mn |
| Dec 31, 2024 | -4.04 Mn |
| Dec 31, 2024 | -4.04 Mn |
| Sep 30, 2024 | 23.41 Mn |
| Sep 30, 2024 | 23.41 Mn |
| Jun 30, 2024 | 893,000.00 |
| Jun 30, 2024 | 893,000.00 |
| Mar 31, 2024 | -456,000.00 |
| Mar 31, 2024 | -456,000.00 |
| Dec 31, 2023 | 15.06 Mn |
| Dec 31, 2023 | 15.06 Mn |